Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

A selective agonist affinity label for A3 adenosine receptors

X D Ji1, C Gallo-Rodriguez, K A Jacobson

  • 1Molecular Recognition Section, National Institute of Diabetes, Digestive and Kidney Diseases, NIH, Bethesda, MD 20892.

Biochemical and Biophysical Research Communications
|August 30, 1994
PubMed
Summary

A novel adenosine derivative selectively targets A3 receptors, irreversibly inhibiting their function. This chemical probe offers a precise tool for studying adenosine A3 receptor pharmacology and potential therapeutic applications.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Prediction of recurrence-free survival of T1 glottic carcinoma based on enhanced CT anterior commissure invasion and tumor volume].

Zhonghua yi xue za zhi·2026
Same author

Purinoceptors in the Central Nervous System.

Drug development research·2024
Same author

The Anti-Cancer Effect of A<sub>3</sub> Adenosine Receptor Agonists: A Novel, Targeted Therapy.

Immunology, endocrine & metabolic agents in medicinal chemistry·2021
Same author

Over-activation of EFTUD2 correlates with tumor propagation and poor survival outcomes in hepatocellular carcinoma.

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·2021
Same author

EFFECT OF NEW PYRIDOXAL PHOSPHATE ARYLAZO DERIVATIVES ON THE ECTO-ATPase ACTIVITY IN GUINEA PIG TISSUES.

Pharmaceutical chemistry journal·2019
Same author

[The correlation between findings of whole-body diffusion weighted imaging and clinical result in patients with multiple myeloma].

Zhonghua yi xue za zhi·2019

Area of Science:

  • Pharmacology
  • Medicinal Chemistry
  • Neuroscience

Background:

  • Adenosine receptors (A1, A2a, A2b, A3) are crucial G protein-coupled receptors involved in various physiological processes.
  • Selective ligands for adenosine receptor subtypes are essential tools for pharmacological research and drug development.
  • The A3 adenosine receptor subtype is implicated in inflammatory and neurological conditions, making it a target of therapeutic interest.

Purpose of the Study:

  • To synthesize and characterize a novel, chemically reactive adenosine derivative for selective A3 receptor targeting.
  • To investigate the binding affinity and selectivity of the new compound across different adenosine receptor subtypes.
  • To determine if the compound can act as an irreversible inhibitor of A3 receptor function.

Main Methods:

Related Experiment Videos

  • Synthesis of N6-(3-isothiocyanatobenzyl)adenosine-5'-N-methyluronamide, a chemically reactive adenosine analogue.
  • Radioligand competition binding assays using [3H] adenosine or other radioligands to determine Ki values at rat A1, A2a, and A3 receptors.
  • Irreversible inhibition studies involving preincubation of the compound with cell membranes expressing specific adenosine receptor subtypes.
  • Concentration-dependent inhibition assays to determine IC50 values and assess the loss of binding sites.

Main Results:

  • The synthesized adenosine derivative demonstrated selective binding to A3 receptors with a Ki of 10.0 nM, compared to 145 nM for A1 and 272 nM for A2a receptors.
  • Preincubation with the derivative resulted in irreversible inhibition of radioligand binding specifically at A3 receptors in transfected cells and mast cells.
  • The irreversible inhibition was concentration-dependent (IC50 = 50 nM) and did not affect the Kd of remaining A3 receptor sites.
  • Adenosine analogues lacking the isothiocyanate group did not cause irreversible inhibition, confirming the role of the reactive group.

Conclusions:

  • N6-(3-isothiocyanatobenzyl)adenosine-5'-N-methyluronamide is a potent and selective A3 adenosine receptor ligand.
  • The compound acts as an irreversible inhibitor, providing a valuable chemical probe for studying A3 receptor function.
  • This selective, irreversible inhibitor holds potential for further research into A3 receptor-mediated physiological and pathological processes.